New drug duo aims to control returning lymphoma
NCT ID NCT04989621
First seen Apr 24, 2026 · Last updated Jun 09, 2026 · Updated 12 times
Summary
This study tests a combination of two drugs (orelabrutinib and rituximab) followed by maintenance orelabrutinib in 32 adults with relapsed or refractory follicular lymphoma. The goal is to see how well the treatment shrinks tumors and how long it keeps the cancer under control. Participants must have had prior treatment and be in adequate health.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for FOLLICULAR LYMPHOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Guangdong General Hospital
RECRUITINGGuangzhou, Guangdong, 510000, China
Contact
-
Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University,
NOT_YET_RECRUITINGGuangzhou, Guangdong, 51000, China
Contact
-
Sun Yat-sen Universitiy Cancer Center, Sun Yat-Sen University,
RECRUITINGGuangzhou, Guangdong, 51000, China
Contact
Conditions
Explore the condition pages connected to this study.